Friday, 6 November 2026European Markets

KEYWARE TECH. Stock Bullish Momentum With A 11% Rise So Far Today

Loading stream...

(VIANEWS) - Shares of KEYWARE TECH. (BEL 20: KEYW.BR) rose by a staggering 11.8% to €1.00 at 11:22 EST on Thursday, following the last session's upward trend. BEL 20 is falling 0.03% to €3,800.71, following the last session's downward trend. This seems, so far, a somewhat bearish trend trading session today.

KEYWARE TECH.'s last close was €1.03, 10.43% under its 52-week high of €1.15.

About KEYWARE TECH.

Keyware Technologies NV, an independent fintech company, provides electronic payment solutions in Belgium. It offers payment transaction software for banks and financial institutions, tokenization software, instalment payment solutions, and ordering and payment app software; and payment processing and management services, as well as engages in the rental and sale of payment terminals. The company was incorporated in 1996 and is headquartered in Zaventem, Belgium.

Earnings Per Share

As for profitability, KEYWARE TECH. has a trailing twelve months EPS of €0.05.

PE Ratio

KEYWARE TECH. has a trailing twelve months price to earnings ratio of 19.9. Meaning, the purchaser of the share is investing €19.9 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.37%.

More news about KEYWARE TECH. (KEYW.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
KEYWARE TECH. Stock Bullish Momentum With A 11% Rise So Far Today | ViaNews EU